HemaCare Co. (OTCMKTS:HEMA – Get Free Report)’s stock price shot up 0.6% during trading on Tuesday . The stock traded as high as $25.31 and last traded at $25.31. 5,400 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 39,950 shares. The stock had previously closed at $25.16.
HemaCare Price Performance
The business’s 50-day simple moving average is $25.31 and its two-hundred day simple moving average is $25.31.
About HemaCare
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy.
Recommended Stories
- Five stocks we like better than HemaCare
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.